Author:
Chang Hsiu-Hao,Lu Meng-Yao,Liao Yu-Mei,Lin Pei-Chin,Yang Yung-Li,Lin Dong-Tsamn,Chiou Shyh-Shin,Jou Shiann-Tarng,Lin Kai-Hsin,Chang Tai-Tsung
Funder
National Taiwan University Hospital
Subject
Oncology,Hematology,Pediatrics, Perinatology, and Child Health
Reference11 articles.
1. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions;Neufeld;Blood,2006
2. Deferasirox (Exjade) for the treatment of iron overload;Cappellini;Acta Haematol,2009
3. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major;Galanello;Haematologica,2006
4. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia;Cappellini;Blood,2006
5. Efficacy and safety of deferasirox doses of >30 mg/kg per day in patients with transfusion-dependent anaemia and iron overload;Taher;Br J Haematol,2009
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献